[go: up one dir, main page]

FR2881350B1 - Nouvelle forme galenique orale de la tianeptine - Google Patents

Nouvelle forme galenique orale de la tianeptine

Info

Publication number
FR2881350B1
FR2881350B1 FR0501056A FR0501056A FR2881350B1 FR 2881350 B1 FR2881350 B1 FR 2881350B1 FR 0501056 A FR0501056 A FR 0501056A FR 0501056 A FR0501056 A FR 0501056A FR 2881350 B1 FR2881350 B1 FR 2881350B1
Authority
FR
France
Prior art keywords
tianeptine
galenic form
new oral
oral galenic
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0501056A
Other languages
English (en)
Other versions
FR2881350A1 (fr
Inventor
Gilles Garcia
Laurence Besse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mylan Generics France Holding SAS
Original Assignee
Mylan Generics France Holding SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mylan Generics France Holding SAS filed Critical Mylan Generics France Holding SAS
Priority to FR0501056A priority Critical patent/FR2881350B1/fr
Publication of FR2881350A1 publication Critical patent/FR2881350A1/fr
Application granted granted Critical
Publication of FR2881350B1 publication Critical patent/FR2881350B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
FR0501056A 2005-02-02 2005-02-02 Nouvelle forme galenique orale de la tianeptine Expired - Lifetime FR2881350B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR0501056A FR2881350B1 (fr) 2005-02-02 2005-02-02 Nouvelle forme galenique orale de la tianeptine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0501056A FR2881350B1 (fr) 2005-02-02 2005-02-02 Nouvelle forme galenique orale de la tianeptine

Publications (2)

Publication Number Publication Date
FR2881350A1 FR2881350A1 (fr) 2006-08-04
FR2881350B1 true FR2881350B1 (fr) 2007-04-06

Family

ID=34954733

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0501056A Expired - Lifetime FR2881350B1 (fr) 2005-02-02 2005-02-02 Nouvelle forme galenique orale de la tianeptine

Country Status (1)

Country Link
FR (1) FR2881350B1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8198268B2 (en) 2008-10-31 2012-06-12 Janssen Biotech, Inc. Tianeptine sulfate salt forms and methods of making and using the same
PL2561864T3 (pl) 2011-08-25 2015-05-29 Zakl Farmaceutyczne Polpharma Sa Tabletka powlekana zawierająca tianeptynę i sposób jej otrzymywania

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2635461B1 (fr) * 1988-08-18 1992-01-17 Adir Utilisation de derives tricycliques pour l'obtention de medicaments destines au traitement du stress
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US6683072B1 (en) * 2003-02-04 2004-01-27 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of irritable bowel syndrome and nonulcer dyspepsia

Also Published As

Publication number Publication date
FR2881350A1 (fr) 2006-08-04

Similar Documents

Publication Publication Date Title
FR2881652B1 (fr) Forme pharmaceutique orale microparticulaire anti-mesuage
FR2892937B1 (fr) Forme pharmaceutique orale microparticulaire anti-mesusage
SMP200600038B (it) Forme di dosaggio di bisfosfonati
PL1901734T3 (pl) Kompozycje zawierające krystaliczny trans-(±)-delta-9-tetrahydrokannabinol
DK1940467T3 (da) Lægemiddelsammensætning med langvarig frigivelse
EP2046290A4 (fr) Formulations aqueuses de dronabinol
EP2012833A4 (fr) Dérivés de la dihydrotétrabénazine radiomarqués et utilisation de ces derniers comme agents d'imagerie
EP2011839A4 (fr) Combinaison d'encres
DK1924151T3 (da) Oral frigivelsessystem med styret frigivelse
BRPI0810928A2 (pt) "composição farmacêutica"
CY2016017I1 (el) Συνθεση για θεραπεια πνευμονικης υπερτασης
BRPI0715621A2 (pt) Formulações galênicas de compostos orgânicos
EP1746141A4 (fr) Composition d' epaississement
PT1850664E (pt) Formulação de cápsulas
EP1997884A4 (fr) Nouvelle population de lymphocytes humains
EP2044926A4 (fr) Composition orale pour applications dentaires
CR9144A (es) Formulaciones de benzoxazoles sustituidos
ATE483497T1 (de) Mundpflegezusammensetzungen
DK1868586T3 (da) Antiinflammatorisk formulering
FR2842993B1 (fr) Nouvelle composition de confiserie
EP2066640A4 (fr) Dérivés d'acétamide 2-(1-oxo-1h-isoquinolin-2-yl)
DK1837019T3 (da) Orale dispergerbare farmaceutiske sammensætninger
FR2900823B1 (fr) Nouvelle forme d'administration du racecadotril.
NO20051467D0 (no) Orale doseringsformer som innbefatter gemcitabinderivater
FR2881350B1 (fr) Nouvelle forme galenique orale de la tianeptine

Legal Events

Date Code Title Description
CA Change of address
CD Change of name or company name
RM Correction of a material error
PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20